Qiagen N.V.QGEN
NYSE•Healthcare•Diagnostics & Research
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Qiagen N.V. (QGEN) reported trailing twelve months revenue of $0 as of December 2025, a NaN% decline year-over-year. Quarterly revenue reached $0, reflecting a contraction in sales.
Qiagen N.V. generated $0 in TTM net income, with quarterly EBITDA of $0. The operating margin stands at 0.0%.
The spread between operating margin (0.0%) and net margin (0.0%) indicates tight cost control with minimal non-operating drag. Net margin has narrowed from 0.0% a year ago, reflecting increased costs or interest expense.
QGEN trades at a P/S of N/A.
The company generated $0 in free cash flow over the trailing twelve months, indicating cash generation ability. The balance sheet shows $6.28B in total assets with $1.65B in long-term debt against $3.78B in stockholders equity for a debt-to-equity ratio of 0.4, a conservative capital structure. Data based on the most recent quarterly reports.
Competitive analysis based on 7 quarters of fundamental data
Operating margins are under pressure, averaging 0.0%. The business may lack pricing power or face rising costs.'
Limited ROE data for a reliable assessment.
Only 0 of the last 7 quarters had positive FCF — the business may require external capital to sustain operations.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 7 quarters
Margins are stable or improving at ~0.0% — no sign of cost or pricing stress.
Insufficient data.
Debt-to-equity has risen 23.9% recently — increasing financial risk even if the current ratio is manageable.
Revenue is stable or growing over recent quarters — demand appears durable.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Share count is stable — no significant dilution or buyback activity.